JP5957526B2 - チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン - Google Patents
チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン Download PDFInfo
- Publication number
- JP5957526B2 JP5957526B2 JP2014530361A JP2014530361A JP5957526B2 JP 5957526 B2 JP5957526 B2 JP 5957526B2 JP 2014530361 A JP2014530361 A JP 2014530361A JP 2014530361 A JP2014530361 A JP 2014530361A JP 5957526 B2 JP5957526 B2 JP 5957526B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazolo
- quinolin
- pyrazol
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- PHJFHVDRXLVFAQ-UHFFFAOYSA-N CN1CCN(Cc2cc(cc(cc3)O)c3nc2)CC1 Chemical compound CN1CCN(Cc2cc(cc(cc3)O)c3nc2)CC1 PHJFHVDRXLVFAQ-UHFFFAOYSA-N 0.000 description 2
- 0 *c1c[n]2c(Sc(cc3)cc4c3ncc(*)c4)nnc2c(*)c1 Chemical compound *c1c[n]2c(Sc(cc3)cc4c3ncc(*)c4)nnc2c(*)c1 0.000 description 1
- QKLMSBGPZMYOMF-UHFFFAOYSA-N Brc1cnc(ccc(OCc2ccccc2)c2)c2c1 Chemical compound Brc1cnc(ccc(OCc2ccccc2)c2)c2c1 QKLMSBGPZMYOMF-UHFFFAOYSA-N 0.000 description 1
- YFCXQUJKPIVRBF-STBIYBPSSA-N C/C(/c(cc1)n[n]2c1nnc2Cc(cc1)cc2c1ncc(N1CCN(C)CC1)c2)=N\OCCO Chemical compound C/C(/c(cc1)n[n]2c1nnc2Cc(cc1)cc2c1ncc(N1CCN(C)CC1)c2)=N\OCCO YFCXQUJKPIVRBF-STBIYBPSSA-N 0.000 description 1
- XDYZXDIUGARRDS-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cc2cc(C(C)=C)ccc2nc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cc2cc(C(C)=C)ccc2nc1)=O XDYZXDIUGARRDS-UHFFFAOYSA-N 0.000 description 1
- IHPJCGNNOPYJQG-UHFFFAOYSA-N CCN(CC1)CCN1c1cnc(ccc([O](C2)C2=C)c2)c2c1 Chemical compound CCN(CC1)CCN1c1cnc(ccc([O](C2)C2=C)c2)c2c1 IHPJCGNNOPYJQG-UHFFFAOYSA-N 0.000 description 1
- TXIOGJHPPVXTOY-UHFFFAOYSA-N CCN1CCN(C)CC1 Chemical compound CCN1CCN(C)CC1 TXIOGJHPPVXTOY-UHFFFAOYSA-N 0.000 description 1
- RMWXBDPPMFXPDI-UHFFFAOYSA-N CN1CCN(Cc2cc3cc(OCc4ccccc4)ccc3nc2)CC1 Chemical compound CN1CCN(Cc2cc3cc(OCc4ccccc4)ccc3nc2)CC1 RMWXBDPPMFXPDI-UHFFFAOYSA-N 0.000 description 1
- IQIXNLSBPCWCMG-CYBMUJFWSA-N C[C@H](C=C)c1ccc2ncc(N3CCOCC3)cc2c1 Chemical compound C[C@H](C=C)c1ccc2ncc(N3CCOCC3)cc2c1 IQIXNLSBPCWCMG-CYBMUJFWSA-N 0.000 description 1
- QWEPGYACBQWDFQ-UHFFFAOYSA-N Oc1cc2cc(N(CC3)CCN3C3CCCCC3)cnc2cc1 Chemical compound Oc1cc2cc(N(CC3)CCN3C3CCCCC3)cnc2cc1 QWEPGYACBQWDFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2011/079695 | 2011-09-15 | ||
| CN2011079695 | 2011-09-15 | ||
| CNPCT/CN2012/079055 | 2012-07-23 | ||
| CN2012079055 | 2012-07-23 | ||
| PCT/IB2012/054775 WO2013038362A1 (en) | 2011-09-15 | 2012-09-13 | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526499A JP2014526499A (ja) | 2014-10-06 |
| JP2014526499A5 JP2014526499A5 (enExample) | 2015-11-05 |
| JP5957526B2 true JP5957526B2 (ja) | 2016-07-27 |
Family
ID=46981017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530361A Expired - Fee Related JP5957526B2 (ja) | 2011-09-15 | 2012-09-13 | チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9062045B2 (enExample) |
| EP (1) | EP2755976B1 (enExample) |
| JP (1) | JP5957526B2 (enExample) |
| KR (1) | KR20140077916A (enExample) |
| AR (1) | AR087868A1 (enExample) |
| AU (1) | AU2012310168B2 (enExample) |
| BR (1) | BR112014006223A8 (enExample) |
| CA (1) | CA2848809A1 (enExample) |
| EA (1) | EA026655B1 (enExample) |
| ES (1) | ES2691650T3 (enExample) |
| MX (1) | MX339302B (enExample) |
| TW (1) | TW201319067A (enExample) |
| UY (1) | UY34329A (enExample) |
| WO (1) | WO2013038362A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105143228B (zh) * | 2013-05-10 | 2017-07-21 | 江苏豪森药业集团有限公司 | [1,2,4]三唑并[4,3‑a]吡啶类衍生物，其制备方法或其在医药上的应用 |
| EP3013825B1 (en) | 2013-06-24 | 2019-08-07 | Amgen Inc. | Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines |
| GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6537591B2 (ja) * | 2014-08-01 | 2019-07-03 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | ｃ−Ｍｅｔ阻害剤の結晶性フリー塩基またはそれらの結晶性酸性塩、およびそれらの製造方法および用途 |
| WO2017049711A1 (zh) | 2015-09-24 | 2017-03-30 | 上海海聚生物科技有限公司 | 喹啉类衍生物、其药物组合物、制备方法及应用 |
| CN106883250B (zh) * | 2015-12-15 | 2021-05-18 | 江苏豪森药业集团有限公司 | C-Met酪氨酸激酶抑制剂的制备方法 |
| SG11202010068VA (en) | 2018-04-25 | 2020-11-27 | Bayer Ag | Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides |
| PH12022550166A1 (en) | 2019-07-23 | 2022-11-14 | Bayer Ag | Novel heteroaryl-triazole compounds as pesticides |
| US12610949B2 (en) | 2019-07-23 | 2026-04-28 | Bayer Aktiengesellschaft | Heteroaryl-triazole compounds as pesticides |
| CN111440174B (zh) * | 2020-04-02 | 2021-07-09 | 广州医科大学 | 一种吡啶酰胺类化合物及其制备方法与应用 |
Family Cites Families (193)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4358453A (en) | 1982-01-08 | 1982-11-09 | Schering Corporation | 1,2,4-Triazolo[4,3-a]pyridines |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| FR2601952B1 (fr) | 1986-07-23 | 1988-11-25 | Carpibem | Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE4326758A1 (de) | 1993-08-10 | 1995-02-16 | Basf Ag | [1,3,4]Triazolo[1,5-a]pyridine |
| DE4329296A1 (de) | 1993-08-31 | 1995-03-02 | Basf Ag | Azofarbstoffe mit einer Diazokomponente aus der Anilinreihe und Kupplungskomponente aus der Triazolopyridinreihe |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| DE938597T1 (de) | 1996-09-06 | 2000-03-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JP4274583B2 (ja) | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） | エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤 |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| AR017457A1 (es) | 1998-02-14 | 2001-09-05 | Glaxo Group Ltd | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| EA200001224A1 (ru) | 1998-06-23 | 2001-08-27 | Глаксо Груп Лимитед | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола |
| GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
| US6303625B1 (en) | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| BR9914526A (pt) | 1998-10-16 | 2001-07-03 | Pfizer | Derivados de adenina |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
| EP2016953A3 (en) | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| JP4673977B2 (ja) | 1999-03-30 | 2011-04-20 | ノバルティス アーゲー | 炎症性疾患治療用フタラジン誘導体 |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| CZ301161B6 (cs) | 1999-05-04 | 2009-11-18 | Schering Corporation | Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující |
| TR200103214T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6333335B1 (en) | 1999-07-23 | 2001-12-25 | Merck & Co., Inc. | Phenyl-protein transferase inhibitors |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| AU6610001A (en) | 2000-06-27 | 2002-01-08 | S A L V A T Lab Sa | Carbamates derived from arylalkylamines |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| DE10038019A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| EP2067784A3 (en) | 2000-08-05 | 2012-08-22 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| HUP0303529A3 (en) | 2000-12-22 | 2008-03-28 | Almirall Ag | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use |
| CN1250545C (zh) | 2000-12-28 | 2006-04-12 | 阿尔米雷尔普罗迪斯制药有限公司 | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| PL366899A1 (en) | 2001-05-25 | 2005-02-07 | Pfizer Inc. | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| ATE399174T1 (de) | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
| EP1578910A4 (en) | 2001-06-21 | 2008-06-04 | Verenium Corp | NITRILASES |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| RU2004110717A (ru) | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| JP4505227B2 (ja) | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| AU2003230700A1 (en) | 2002-03-26 | 2003-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| PL373043A1 (en) | 2002-03-26 | 2005-08-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1496911B1 (en) | 2002-04-10 | 2007-12-19 | University Of Virginia Patent Foundation | Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| ATE356808T1 (de) | 2002-06-25 | 2007-04-15 | Merck Frosst Canada Ltd | 8-(biaryl)chinolin-pde4-inhibitoren |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| WO2004005258A1 (en) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| ES2518940T3 (es) | 2002-07-08 | 2014-11-06 | Pfizer Products Inc. | Moduladores del receptor de glucocorticoides |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| CA2494650A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| HRP20050197A2 (en) | 2002-08-10 | 2006-06-30 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| JP2005538140A (ja) | 2002-08-10 | 2005-12-15 | アルタナ ファルマ アクチエンゲゼルシャフト | Ｐｄｅ４インヒビターとしてのピペリジン−ピリダゾン及びフタラゾン |
| AU2003263216A1 (en) | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Benzonaphthyridines with PDE 3/4 inhibiting activity |
| PL374014A1 (en) | 2002-08-17 | 2005-09-19 | Altana Pharma Ag | Novel phenanthridines having pde 3/4 inhibiting properties |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| JP2006501236A (ja) | 2002-08-23 | 2006-01-12 | ランバクシー ラボラトリーズ リミテッド | ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体 |
| US7423046B2 (en) | 2002-08-29 | 2008-09-09 | Nycomed Gmbh | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| AU2003255493B8 (en) | 2002-08-29 | 2009-03-26 | Takeda Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
| EP1537107A2 (en) | 2002-08-30 | 2005-06-08 | Pfizer Products Inc. | Novel processes and intermediates for preparing triazolo-pyridines |
| KR20050057408A (ko) | 2002-09-18 | 2005-06-16 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제 |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004037805A1 (en) | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US20050256309A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US20090215817A1 (en) | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| US7579348B2 (en) | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| CL2007000851A1 (es) | 2006-03-30 | 2008-03-14 | Novartis Ag | Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| EP2032578A2 (en) | 2006-05-30 | 2009-03-11 | Pfizer Products Incorporated | Triazolopyridazine derivatives |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR101083177B1 (ko) | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| CA2667428A1 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| ES2560435T3 (es) | 2006-11-22 | 2016-02-19 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
| EP2170894A1 (en) | 2007-06-21 | 2010-04-07 | Janssen Pharmaceutica N.V. | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| EP2183254B1 (en) | 2007-08-29 | 2017-06-21 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US20110039856A1 (en) | 2007-11-29 | 2011-02-17 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
| JP2011506335A (ja) | 2007-12-06 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
| MX393622B (es) | 2008-05-21 | 2025-03-24 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
| WO2010007316A2 (fr) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941951B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| JP2012528188A (ja) | 2009-05-28 | 2012-11-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔタンパク質キナーゼの阻害剤 |
| PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| MX2012002179A (es) * | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| MX2012009378A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Compuestos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno y pirazolotiazol como potenciadores alostericos mglur4, composiciones y metodos para tratar disfunciones neurologicas. |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| EP2425830A1 (en) | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| US20120100157A1 (en) | 2010-10-11 | 2012-04-26 | Van Andel Research Institute | Biomarker and Method for Predicting Sensitivity to MET Inhibitors |
| JP2014505088A (ja) * | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
-
2012
- 2012-09-13 UY UY0001034329A patent/UY34329A/es not_active Application Discontinuation
- 2012-09-13 ES ES12769172.3T patent/ES2691650T3/es active Active
- 2012-09-13 US US13/613,291 patent/US9062045B2/en active Active
- 2012-09-13 EP EP12769172.3A patent/EP2755976B1/en not_active Not-in-force
- 2012-09-13 EA EA201490630A patent/EA026655B1/ru not_active IP Right Cessation
- 2012-09-13 AU AU2012310168A patent/AU2012310168B2/en not_active Ceased
- 2012-09-13 KR KR1020147009795A patent/KR20140077916A/ko not_active Withdrawn
- 2012-09-13 BR BR112014006223A patent/BR112014006223A8/pt not_active IP Right Cessation
- 2012-09-13 CA CA2848809A patent/CA2848809A1/en not_active Abandoned
- 2012-09-13 JP JP2014530361A patent/JP5957526B2/ja not_active Expired - Fee Related
- 2012-09-13 WO PCT/IB2012/054775 patent/WO2013038362A1/en not_active Ceased
- 2012-09-13 MX MX2014003194A patent/MX339302B/es active IP Right Grant
- 2012-09-14 AR ARP120103386A patent/AR087868A1/es unknown
- 2012-09-14 TW TW101133879A patent/TW201319067A/zh unknown
-
2015
- 2015-05-19 US US14/716,159 patent/US9474762B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014006223A2 (pt) | 2017-04-11 |
| WO2013038362A1 (en) | 2013-03-21 |
| AU2012310168B2 (en) | 2015-07-16 |
| US9062045B2 (en) | 2015-06-23 |
| US20150250799A1 (en) | 2015-09-10 |
| AR087868A1 (es) | 2014-04-23 |
| TW201319067A (zh) | 2013-05-16 |
| CA2848809A1 (en) | 2013-03-21 |
| BR112014006223A8 (pt) | 2018-01-09 |
| ES2691650T3 (es) | 2018-11-28 |
| JP2014526499A (ja) | 2014-10-06 |
| EA201490630A1 (ru) | 2014-08-29 |
| EP2755976B1 (en) | 2018-07-18 |
| US20130245002A1 (en) | 2013-09-19 |
| MX339302B (es) | 2016-05-19 |
| EP2755976A1 (en) | 2014-07-23 |
| UY34329A (es) | 2013-04-30 |
| MX2014003194A (es) | 2015-03-19 |
| AU2012310168A1 (en) | 2014-05-01 |
| EA026655B1 (ru) | 2017-05-31 |
| US9474762B2 (en) | 2016-10-25 |
| KR20140077916A (ko) | 2014-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2691650T3 (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met | |
| JP5576802B2 (ja) | Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| KR101277823B1 (ko) | 피롤로［２,３ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도 | |
| US8410264B2 (en) | Heterocyclic oxime compounds | |
| JP6649540B2 (ja) | 置換されたヘテロアリール化合物および使用方法 | |
| JP6564406B2 (ja) | カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体 | |
| JP2022518505A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| JP2010526120A (ja) | Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン | |
| JP2016507502A (ja) | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール | |
| ES2426405T3 (es) | Derivados de 3-heteroaril-metil-imidazo[1,2-b]piridazin-6-ilo como moduladores de tirosina quinasa c-Met | |
| JP2018527362A (ja) | 置換されたヘテロアリール化合物および使用方法 | |
| US20130324526A1 (en) | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase | |
| CN103958509B (zh) | 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物 | |
| CN103459396B (zh) | 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物 | |
| CN115843296B (zh) | Cdk9抑制剂及其用途 | |
| TW202506680A (zh) | 作為ｐａｒｐ１抑制劑之雜環化合物 | |
| WO2024226914A2 (en) | Mrgprx2 antagonists and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140805 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150908 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150908 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160513 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160607 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160620 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5957526 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |